Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synairgen Supercharges R&D With $100m Financing

To Support COVID-19 Study Of Inhaled Beta-Interferon

Executive Summary

With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.

You may also be interested in...



Synairgen Aims To Disprove Doubts About Interferon Therapy In COVID-19

The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study

UK Biotech Defies Pandemic, On Course For Record Fundraising Year

The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.

GSK’s Emma Walmsley Made A Dame In UK Honors

Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel